In prior adult Phase 1/2 data, VAX-31 produced robust opsonophagocytic activity across all 31 serotypes, met superiority criteria on all 11 serotypes not covered by PCV20, and delivered higher average OPA responses for 18 of the 20 shared serotypes, with seven reaching statistical superiority, on a safety profile similar to PCV20. That signal underpins FDA’s expanded Breakthrough Therapy designation for prevention of pneumococcal pneumonia and IPD and sets the bar for the pivotal program now underway.
Vaxcyte has dosed first participants in OPUS-3, a Phase 3 study in adults previously vaccinated with pneumococcal vaccines, while continuing enrollment in OPUS-1, a noninferiority trial intended to support prevention claims in adults, and OPUS-2, a concomitant administration study with seasonal influenza vaccine in pneumococcal-naïve adults. Across OPUS-1/2/3, the company plans to enroll roughly 6,000 adults, about 3,400 of whom will receive VAX-31. Topline from OPUS-1 is guided for Q4 2026, with OPUS-2 and OPUS-3 readouts in the first half of 2027, alongside a lot-to-lot manufacturing consistency study to complete a planned BLA package agreed with FDA.
Strategically, Vaxcyte is making a breadth-first bid to leapfrog entrenched adult options by moving straight to a 31-valent construct designed to capture approximately 95% of IPD and 88% of pneumococcal pneumonia in U.S. adults 50+. The competitive lens is clear: Pfizer’s PCV20 has scale and guideline traction, and Merck’s adult-focused PCV has expanded serotype coverage relative to legacy products. VAX-31 is positioned to compete on incremental population coverage and on immunologic strength versus PCV20 across shared serotypes. The tension is whether regulators, ACIP, and payers will treat immunobridging superiority and breadth as sufficient for practice change, given the operational and CMC complexity inherent to a 31-valent conjugate.
For sites and CROs, OPUS-3 introduces real-world complexity as a core design feature. Stratifying adults by prior vaccination with PPSV23, PCV20, or mixed histories reflects how switching and boosting will play out operationally; it also raises screening burden, source data verification around historical vaccines, and the need to manage potential hyporesponsiveness following polysaccharide priming. The 3:1 randomization against PCV20 concentrates safety exposure in VAX-31 while maintaining a relevant comparator. OPUS-2’s concomitant flu study aligns with how adult vaccines are administered in practice, but it compresses enrollment into seasonal windows and adds assay and logistics load to demonstrate noninterference. Central OPA and IgG testing at Month 1, with six months of safety follow-up, will drive sample and cold-chain coordination and place pressure on specialized immunology labs.
Regulators will focus on three executional choke points: assay durability and cross-lab reproducibility for OPA readouts, consistency across manufacturing lots in a high-valency product, and immunogenicity performance in previously vaccinated cohorts where PPSV23 priming can blunt responses. ACIP modeling of serotype epidemiology and projected disease impact will determine whether incremental coverage translates into recommendation changes or preferential use, a prerequisite for commercial uptake in a crowded adult market. Competitors will respond with their own breadth claims, postmarketing effectiveness data, and contracting strategies; supply reliability and presentation format may be as decisive as immunology.
The near-term watch list is straightforward: OPUS-1 noninferiority across shared serotypes and superiority on incremental serotypes, reactogenicity at 31-valent scale, noninterference with flu coadministration, and clean lot-to-lot outcomes. If those pieces hold and FDA is comfortable with the immunobridging package, VAX-31 could be positioned for a 2027 BLA and a 2028 ACIP cycle. The unresolved risk is executional: translating a strong Phase 1/2 signal into consistent, scalable manufacturing and reproducible immunogenicity across diverse adult vaccination histories.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
